{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:13:10Z","timestamp":1790223190825,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["PDF\/2016\/002436"],"award-info":[{"award-number":["PDF\/2016\/002436"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009053","name":"The Wellcome Trust DBT India Alliance","doi-asserted-by":"publisher","award":["IA\/S\/14\/1\/501307"],"award-info":[{"award-number":["IA\/S\/14\/1\/501307"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.tips.2019.08.008","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T08:39:41Z","timestamp":1570783181000},"page":"811-817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["You Cannot Have Your Synergy and Efficacy Too"],"prefix":"10.1016","volume":"40","author":[{"given":"Pramita","family":"Sen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9828","authenticated-orcid":false,"given":"Narendra M.","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2019.08.008_bb0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tips.2019.08.008_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.tips.2019.08.008_bb0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","article-title":"Quantifying drug combination synergy along potency and efficacy axes","volume":"8","author":"Meyer","year":"2019","journal-title":"Cell Syst."},{"key":"10.1016\/j.tips.2019.08.008_bb0020","first-page":"2027","article-title":"The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity","volume":"4","author":"Frei","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2019.08.008_bb0025","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.2649","article-title":"A quantitative basis for antiretroviral therapy for HIV-1 infection","volume":"18","author":"Jilek","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2019.08.008_bb0030","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1073\/pnas.1610197114","article-title":"Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection","volume":"114","author":"Koizumi","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2019.08.008_bb0035","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nprot.2016.017","article-title":"Optimization of drug combinations using feedback system control","volume":"11","author":"Nowak-Sliwinska","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.tips.2019.08.008_bb0040","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/bioinformatics\/btx806","article-title":"DeepSynergy: predicting anti-cancer drug synergy with deep learning","volume":"34","author":"Preuer","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.tips.2019.08.008_bb0045","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modelling how ribavirin improves interferon response rates in hepatitis C virus infection","volume":"432","author":"Dixit","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.tips.2019.08.008_bb0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/gutjnl-2013-306155","article-title":"Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C","volume":"64","author":"Xiao","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.tips.2019.08.008_bb0055","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90033","article-title":"Quantitative evaluation of the antiretroviral efficacy of dolutegravir","volume":"1","author":"Laskey","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.tips.2019.08.008_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006004","article-title":"Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents","volume":"14","author":"Gupta","year":"2018","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.tips.2019.08.008_bb0065","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41389-018-0084-0","article-title":"Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma","volume":"7","author":"de Jong","year":"2018","journal-title":"Oncogenesis"},{"key":"10.1016\/j.tips.2019.08.008_bb0070","doi-asserted-by":"crossref","first-page":"12480","DOI":"10.1073\/pnas.1516208112","article-title":"Selective targeting of\u00a0JAK\/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2019.08.008_bb0075","series-title":"Virus Dynamics: Mathematical Principles of Immunology and Virology","author":"Nowak","year":"2000"},{"key":"10.1016\/j.tips.2019.08.008_bb0080","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.tips.2019.08.008_bb0085","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/psp4.12005","article-title":"Modeling suggests a mechanism of synergy between hepatitis C virus entry inhibitors and drugs of other classes","volume":"4","author":"Padmanabhan","year":"2015","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.tips.2019.08.008_bb0090","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrmicro2133","article-title":"Drug interactions and the evolution of antibiotic resistance","volume":"7","author":"Yeh","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.tips.2019.08.008_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fphar.2015.00181","article-title":"What is synergy? The Saariselka agreement revisited","volume":"6","author":"Tang","year":"2015","journal-title":"Front. Pharmacol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614719301944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614719301944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:50:39Z","timestamp":1777495839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614719301944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0165614719301944"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2019.08.008","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"You Cannot Have Your Synergy and Efficacy Too","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2019.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}